Source: MarketScreener

i2o Therapeutics: i2O Therapeutics : Announces Research Collaboration with Sanofi to Enable Oral Delivery of Nanobody-based Medicines

(marketscreener.com) Partnership to create new treatment delivery options for people facing serious diseases https://www.marketscreener.com/news/latest/i2O-Therapeutics-Announces-Research-Collaboration-with-Sanofi-to-Enable-Oral-Delivery-of-Nanobody--32406802/?utm_medium=RSS&utm_content=20210210

Read full article »

i2o Therapeutics's Competitors | i2o Therapeutics's News | i2o Therapeutics's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

Chairman & CEO

Kurt Graves

CEO Approval Rating

90/100

i2o is a Massachusetts-based biotechnology company that researches and develops oral peptide and protein therapies for the treatment of cardiometabolic diseases.